查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1844414

神经復健设备市场按设备类型、应用、最终用户、技术和年龄组别划分－2025-2032年全球预测

Neurorehabilitation Devices Market by Device Type, Application, End User, Technology, Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，神经復健设备市场规模将达到 26.2 亿美元，复合年增长率为 7.97%。

主要市场统计数据
基准年 2024 14.2亿美元
预计年份：2025年 15.3亿美元
预测年份：2032年 26.2亿美元
复合年增长率 (%) 7.97%

全面审视当代临床压力、相关人员的期望以及技术主导的神经復健设备采用和护理服务重塑之路。

神经復健设备正处于临床需求与快速技术进步的交汇点，其发展动力源于恢復神经系统疾病患者的功能、减轻残疾程度并提高生活品质的需求。临床医生日益需要能够整合精准诊断、适应性治疗方法和可衡量疗效的解决方案，而支付方和医疗服务提供者则要求透过提高功能独立性和降低长期照护成本来证明其价值。因此，开发人员正优先考虑互通性、以使用者为中心的设计和循证实践，以缩短从技术创新到临床应用的路径。

目前，重点正转向能够实现跨不同医疗环境（从急诊医院到门诊復健中心再到居家照护）的连续性护理和远端监测的设备。因此，监管策略、临床检验和真实世界表现数据正成为商业性成功的关键决定因素。在此转变过程中，相关人员必须平衡漫长的研发週期和复杂的报销环境，以及人们对个人化和可扩展临床工作流程日益增长的期望。

融合技术、分散式护理模式和以价值主导的证据要求如何推动神经復健设备开发和交付领域的模式转移

神经復健领域正经历多重变革时期，重塑治疗方法的研发、报销和实施方式。感测、驱动和机器学习技术的进步，使得设备能够提供适应性治疗方案，并近乎即时地回应患者的復原进展。同时，机器人技术、神经调控、脑机介面和身临其境型虚拟环境的融合，正将治疗的可能性推向传统框架之外，从而实现针对运动、认知和感觉功能恢復的多模态干预。

与此同时，临床实践模式正朝着分散式医疗模式发展。这种转变推动了对轻鬆易用设备的需求，这些设备能够支援居家治疗和临床医生指导的远距会诊。支付者和医疗系统正在应对人口老化和慢性神经系统疾病盛行率上升的问题，优先考虑那些能够带来长期功能改善并降低后续成本的干预措施。因此，产品开发蓝图强调报销策略、追踪长期疗效以及累积证据以检验持续的临床有效性。最终，这些因素共同加速了从个别设备转变为整合式医疗平台的转变，从而建构一个将患者、临床医生和数据连接起来的连续性医疗生态系统。

2025年关税调整对供应链、筹资策略和区域製造业的影响：神经復健设备相关人员的考量

2025年实施的关税和贸易措施为依赖跨境供应链取得零件和成品设备的製造商、供应商和医疗保健系统带来了新的营运和策略考量。对于进口专用电子产品、感测器和驱动系统的公司而言，关税带来的额外成本促使它们重新评估采购筹资策略、供应商多元化和近岸外包方案。因此，采购团队和营运负责人正专注于分析到岸成本、总拥有成本和库存弹性，以降低潜在的价格波动和供应中断风险。

这些动态也影响产品蓝图和商业化策略。拥有全球分销网络的公司正在评估定价模式和合约条款，以保护利润率并在关键地区保持竞争力。同时，策略伙伴关係和对区域製造的投资正日益受到关注，被视为避免贸易摩擦和缩短前置作业时间的途径。对于临床和研究机构而言，由于新的关税相关成本压力，它们需要重新评估资本预算和耗材供应承诺，因此采购週期可能会延长，这也使得透明的价值提案和可靠的卫生经济学证据变得更加重要。

可操作的细分框架，将设备原型、临床适应症、护理环境、实行技术和患者人口统计特征联繫起来，为产品和测试设计提供资讯。

有效的市场区隔对于了解创新将在哪些领域产生最大的临床和商业性影响至关重要，而从设备类型、应用、最终用户、技术和年龄组等多个维度进行细緻分析，可以揭示不同的应用管道。按设备类型划分，市场包括生物回馈疗法系统、外骨骼、功能性电刺激设备、神经调控设备和虚拟实境系统。在生物回馈疗法系统中，肌电生物回馈疗法和压力生物回馈疗法有所区别；外骨骼分为下肢和上肢两种配置；功能性电刺激设备分为植入式和表面式；神经调控设备分为侵入式和非侵入式；虚拟实境系统则分为身临其境型和非身临其境型。依应用划分，临床适应症包括脑性麻痹、多发性硬化症、巴金森氏症、脊髓损伤和中风。脑性麻痹亚型包括共济失调型、运动障碍型和痉挛型。多发性硬化症的病程分为进行型和復发缓解型。帕金森氏症通常分为晚期和早期。脊髓损伤分为完全性损伤和不完全性损伤。中风病例依病因分为出血性和缺血性。按最终用户划分，部署地点涵盖诊所、居家照护、医院、復健中心和研究机构。诊所分为综合诊所和专科诊所，居家照护分为辅助生活和自我管理，医院分为私立医院和公立医院，復健中心分为住院部和门诊部，研究机构分为学术型和私立型。依技术划分，关键技术包括脑机介面、机器人技术、经颅直流电刺激、经颅磁刺激和虚拟实境。脑机介面进一步分为侵入式和非侵入式两种模式，机器人技术分为末端执行器系统和外骨骼系统，经颅直流电刺激（TDS）分为阳极模式和阴极模式，经颅磁刺激（TMS）分为dTMS和rTMS两种变体，虚拟实境技术分为身临其境型和非身临其境型。就年龄层而言，患者群体涵盖成人、老年人和儿童。成人通常分为18-40岁、41-64岁及65岁以上三个年龄层；老年患者分为65-74岁、75-84岁及85岁以上三个年龄层；儿童包括青少年、儿童及新生儿。

这些细分维度的重迭为产品开发和临床检验创造了多个方向。例如，专为门诊復健中心早期帕金森氏症患者设计的身临其境型虚拟实境系统，与旨在用于居家照护中不完全性脊髓损伤復健的表面功能性电刺激设备，其临床证据和商业化路径将截然不同。因此，企业必须根据设备类型、治疗适应症、护理环境、实行技术和患者年龄组的具体交集，调整其监管策略、临床研究设计和实施流程，以最大限度地提高产品的普及率和治疗相关性。

影响美洲、欧洲、中东和非洲以及亚太地区临床应用、报销方式和生产策略的区域性因素

区域动态影响临床应用、报销政策和供应链策略，三大宏观区域各自呈现不同的机会和挑战。在美洲，分散的医疗服务体系、完善的支付系统和活跃的创业投资活动为技术先进的医疗器械的商业化提供了支持，但联邦和私人支付方在报销方面的差异，使得协调卫生经济学证据和区域市场推广计划变得至关重要。欧洲、中东和非洲的特点是管理体制、基础设施和公私医疗服务提供者的多样性，这需要灵活的分销模式和伙伴关係策略。在部分地区，如果证据达到政策门槛，集中化的报销机构可以加速技术应用；而在中东和非洲的其他地区，则需要进行区域试点测试以验证可行性。亚太地区展现出快速的都市区应用、强大的製造能力和不断发展的报销管道。此外，该地区对可扩展、经济高效的解决方案有着很高的需求，这些解决方案能够满足庞大的患者群体和多样化的医疗基础设施的需求。

在这些地区，相关人员必须考虑临床实践模式、看护者配备和数位化医疗应对力程度的差异。因此，整合区域特定临床检验、报销文件和培训项目的打入市场策略将有助于实现永续推广。此外，建立策略性区域伙伴关係、投资本地监管专业知识以及进行有针对性的价值沟通，对于弥合这些不同地区之间的临床证据与采购决策之间的鸿沟至关重要。

竞争动态和能力需求将影响神经復健设备生态系中的领导地位、伙伴关係模式和附加价值服务差异化。

神经復健设备生态系统的竞争动态由成熟的医疗技术公司、专注于特定领域的精品开发商、学术衍生公司以及跨行业新秀共同构成。主要企业强调其多学科研发能力、完善的监管管道和广泛的临床证据项目，而规模较小的创新者则往往专注于特定适应症、颠覆性技术以及能够加速临床检验的策略联盟。在整个竞争格局中，与学术中心、大型医疗系统或零件供应商合作已成为加速产品迭代和增强临床可靠性的核心机制。

此外，差异化服务模式正逐渐成为竞争优势。将设备与远端监测、分析和临床支援软体平台结合的公司，能够为那些重视长期疗效评估的购买者提供更高的感知价值。围绕着演算法、感测器融合和治疗交付的智慧财产权，以及在不同患者群体中展现可重复疗效提升的能力，都会影响竞争地位。因此，各公司正增加对疗效研究、支付方合作和可扩展生产的投资，以增强商业性防御能力。

领导者必须采取切实可行的策略措施，将临床证据、模组化产品开发、供应链韧性和支付方参与相结合，以实现永续成长。

产业领导者应采取双管齐下的策略，平衡近期商业化与长期平台开发。首先，优先针对具有高影响力的适应症和拥有成熟报销管道的医疗环境，产生临床证据，从而打造能够推动支付方参与和临床医生支持的标竿案例。同时，投资于模组化产品架构和支援迭代更新的软体服务，使企业能够在无需彻底重新设计硬体的情况下，扩展治疗适应症和护理路径。

第二，我们正透过策略性供应商多元化、投资区域製造以及灵活的采购协议来增强供应链韧性，以降低关税引发的成本波动和零件短缺的风险。第三，我们正与医疗系统、復健网络和学术中心建立伙伴关係，共同开发培训课程、远距监测工作流程和价值文件，使临床结果与采购需求相符。最后，我们将可靠的上市后证据收集和卫生经济学模型融入商业运营，将临床结果转化为对支付方提案相关的价值主张，从而加快医保覆盖决策和机构采购。

透过透明的多方法研究途径，结合一手临床访谈、专家文献综述、监管审查和供应商格局分析，以获得可靠的洞察。

我们的研究途径结合了多方资讯来源收集和专家咨询，建构了一个严谨且可重复的分析基础。主要研究包括对临床医生、采购负责人和技术开发人员进行结构化访谈，以了解实际应用中的挑战、临床优先事项和驱动因素。次要研究则检验了同侪审查的临床文献、监管指导文件和公开的技术规格中的设备特性和临床应用案例。此外，供应商格局分析和专利分析也让我们深入了解了技术差异化和智慧财产权趋势。

数据综合分析将定性见解与定量营运指标（例如临床试验活动、监管核准和已发表的健康结果）进行三角验证。透过应用标准化标准（包括证据权重、假设透明度和重复的同侪检验） ，检验了调查方法的严谨性。这种方法确保结论能够反映临床实际情况、监管限制以及与相关人员在整个开发、部署和采购生命週期中相关的商业性需求。

整合技术整合、政策转变和商业需求，为将神经復健创新转化为临床影响的策略重点提供基础。

总之，神经復健设备生态系统正从一系列独立技术的集合演变为一个以持续护理、可验证的疗效和可扩展的交付为优先的综合治疗平台。包括机器人技术、神经调控、脑机介面和身临其境型环境在内的技术融合，在拓展治疗选择的同时，也提高了临床检验和互通性的门槛。同时，政策变化、价格波动和区域医疗保健差异正在重塑供应链、定价策略和产品上市时间。

为了应对这一复杂的局面，相关人员需要将产品设计与特定的临床路径相匹配，投资于能够引起支付方和医疗服务提供方共鸣的证据，并建立能够适应地缘政治和监管变化的稳健营运模式。那些将严谨的临床科学与务实的商业化策略和合作伙伴关係相结合的公司，将更有能力将创新转化为持续的患者获益和组织发展。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 引入封闭回路型神经调控系统进行个人化中风復健治疗
  • 将穿戴式外骨骼与脑机介面结合，以增强运动后恢復。
  • 利用虚拟实境和游戏化技术提高患者参与神经復健计画的积极性
  • 超音波神经调控技术在神经系统疾病非侵入性治疗的应用进展
  • 具备远端监控和远端医疗功能的家用机器人復健设备发展迅速
  • 人工智慧驱动的预测分析的出现，为优化个人化神经復健治疗管道奠定了基础
  • 开发一种可植入式神经探针，实现即时监测和自适应刺激通讯协定

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 神经復健设备市场（依设备类型划分）

  • 生物回馈疗法系统
    • 肌电生物回馈疗法
    • 压力生物回馈疗法
  • 外骨骼
    • 下肢
    • 上肢
  • 功能性电刺激设备
    • 嵌入式
    • 表面
  • 神经调节装置
    • 侵入性
    • 非侵入性
  • 虚拟实境系统
    • 身临其境型
    • 非身临其境型

第九章 按应用分類的神经復健设备市场

  • 脑性麻痹
    • 共济失调
    • 运动障碍
    • 痉挛
  • 多发性硬化症
    • 进步
    • 復发缓解型
  • 帕金森氏症
    • 晚期
    • 早期的
  • 脊髓损伤
    • 完成
    • 未完成
  • 中风
    • 出血性
    • 缺血性

第十章 依最终使用者分類的神经復健设备市场

  • 诊所
    • 一般的
    • 专业
  • 居家医疗
    • 辅助生活设施
    • 自我管理
  • 医院
    • 私人的
    • 公共
  • 復健中心
    • 住院治疗
    • 门诊
  • 研究所
    • 学术的
    • 私人的

第十一章 按科技分類的神经復健设备市场

  • 脑机介面
    • 侵入性
    • 非侵入性
  • 机器人技术
    • 末端执行器
    • 外骨骼
  • 经颅直流电刺激
    • 阳极
    • 阴极
  • 经颅磁刺激
    • dTMS
    • rTMS
  • 虚拟实境
    • 身临其境型
    • 非身临其境型

第十二章 按年龄组别分類的神经復健设备市场

  • 成人
    • 18至40岁
    • 41至64岁
    • 65岁或以上
  • 老年人
    • 65-74岁
    • 75至84岁
    • 85岁或以上
  • 孩子们
    • 青春期
    • 婴儿
    • 新生

第十三章 各地区神经復健设备市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 神经復健设备市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国神经復健设备市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Medtronic plc
    • Bioness, Inc.
    • Hocoma AG
    • Tyromotion GmbH
    • Ekso Bionics Operations, Inc.
    • ReWalk Robotics Ltd.
    • Myomo, Inc.
    • Bionik Laboratories Corp.
    • Cyberdyne Inc.
    • Hasomed GmbH
Product Code: MRR-710B1F0AC5A5

The Neurorehabilitation Devices Market is projected to grow by USD 2.62 billion at a CAGR of 7.97% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.42 billion
Estimated Year [2025] USD 1.53 billion
Forecast Year [2032] USD 2.62 billion
CAGR (%) 7.97%

Comprehensive orientation to contemporary clinical pressures, stakeholder expectations, and technology-driven pathways reshaping neurorehabilitation device adoption and care delivery

Neurorehabilitation devices sit at the intersection of clinical need and rapid technological advancement, driven by the imperative to restore function, reduce disability, and improve quality of life for patients with neurological conditions. Clinicians increasingly demand solutions that integrate precise diagnostics, adaptive therapy delivery, and measurable outcomes, while payers and providers seek demonstrable value through improved functional independence and reduced long-term care costs. As a result, developers are prioritizing interoperability, user-centered design, and evidence generation to shorten the path from innovation to clinical adoption.

Across diverse care settings, from acute hospitals to outpatient rehabilitation centers and home-based care, the emphasis is shifting toward devices that enable continuity of care and remote monitoring. Consequently, regulatory strategy, clinical validation, and real-world performance data have become core determinants of commercial success. In light of these dynamics, stakeholders must reconcile long development cycles and complex reimbursement environments with a growing expectation for personalization and scalable clinical workflows.

How converging technologies, decentralized care models, and value-driven evidence requirements are catalyzing a paradigm shift in neurorehabilitation device development and delivery

The neurorehabilitation landscape is undergoing multiple transformative shifts that are rewriting how therapies are developed, reimbursed, and delivered. Advances in sensing, actuation, and machine learning have enabled devices to offer adaptive therapy regimens that respond to patient progress in near real time. Simultaneously, the convergence of robotics, neuromodulation, brain-computer interfaces, and immersive virtual environments is expanding therapeutic possibilities beyond traditional boundaries, enabling multi-modal interventions that target motor, cognitive, and sensory recovery.

At the same time, clinical practice patterns are evolving toward decentralized care models. This shift increases demand for lightweight, user-friendly devices that support home-based therapy and clinician-supervised remote sessions. Payers and health systems are responding to population aging and rising chronic neurological disease prevalence by prioritizing interventions that demonstrate long-term functional gains and reduced downstream costs. As a result, product development roadmaps emphasize reimbursement strategy, longitudinal outcome tracking, and evidence generation to validate sustained clinical impact. Ultimately, these combined forces are accelerating a transition from discrete devices to integrated care platforms that connect patients, clinicians, and data in continuous therapeutic ecosystems.

Implications of 2025 tariff adjustments on supply chains, procurement strategies, and regional manufacturing considerations for neurorehabilitation device stakeholders

Tariff policies and trade measures instituted in 2025 introduced new operational and strategic considerations for manufacturers, suppliers, and health systems that rely on cross-border supply chains for components and finished devices. For firms that import specialized electronics, sensors, and actuation systems, the added costs associated with tariffs have prompted reassessments of sourcing strategy, supplier diversification, and nearshoring options. In turn, procurement teams and operations leaders have increased focus on landed cost analysis, total cost of ownership, and inventory resilience to mitigate potential price volatility and supply disruptions.

These dynamics have also influenced product roadmaps and commercialization tactics. Companies with global distribution networks are evaluating pricing models and contractual terms to preserve competitiveness in key regions while protecting margins. Meanwhile, strategic partnerships and regional manufacturing investments have gained traction as a way to circumvent trade frictions and shorten lead times. For clinical and research institutions, procurement cycles may lengthen as organizations re-evaluate capital budgets and consumable supply commitments in light of new tariff-related cost pressures, which reinforces the need for transparent value propositions and robust health economic evidence.

Actionable segmentation framework linking device archetypes, clinical indications, care settings, enabling technologies, and patient age groups to inform product and trial design

Effective segmentation is critical to understanding where innovations will have the greatest clinical and commercial impact, and a nuanced view across device type, application, end user, technology, and age group reveals distinct adoption pathways. Based on device type, the landscape includes biofeedback systems, exoskeletons, functional electrical stimulation devices, neuromodulation devices, and virtual reality systems; within biofeedback systems, distinctions arise between EMG biofeedback and pressure biofeedback, while exoskeletons bifurcate into lower limb and upper limb configurations, functional electrical stimulation devices differentiate between implantable and surface approaches, neuromodulation devices are classified as invasive or noninvasive, and virtual reality systems range from immersive to nonimmersive experiences. Based on application, clinical indications encompass cerebral palsy, multiple sclerosis, Parkinson's disease, spinal cord injury, and stroke; cerebral palsy subtypes include ataxic, dyskinetic, and spastic presentations, multiple sclerosis courses separate into progressive and relapsing remitting forms, Parkinson's disease is commonly considered in advanced and early stages, spinal cord injury is categorized as complete or incomplete, and stroke cases are differentiated into hemorrhagic and ischemic etiologies. Based on end user, deployments vary across clinics, home care, hospitals, rehabilitation centers, and research institutes; clinics split into general and specialty practices, home care is distinguished between assisted living and self-managed contexts, hospitals differ by private and public status, rehabilitation centers operate as inpatient or outpatient facilities, and research institutes are either academic or private. Based on technology, key enablers include brain-computer interfaces, robotics, transcranial direct current stimulation, transcranial magnetic stimulation, and virtual reality; brain-computer interfaces further separate into invasive and noninvasive modalities, robotics divides into end effector and exoskeleton systems, transcranial direct current stimulation is categorized into anodal and cathodal modes, transcranial magnetic stimulation appears as dTMS and rTMS variants, and virtual reality technologies split into immersive and nonimmersive formats. Based on age group, patient segments span adult, geriatric, and pediatric populations; adults are commonly profiled across ages 18 to 40, 41 to 64, and 65 plus, geriatric cohorts are often delineated as 65 to 74, 75 to 84, and 85 plus, and pediatric patients encompass adolescent, childhood, and neonatal stages.

Taken together, these layered segmentation dimensions create multiple vectors for product development and clinical validation. For example, an immersive virtual reality system designed for early-stage Parkinson's disease in an outpatient rehabilitation center will follow a different clinical evidence and commercialization path than a surface functional electrical stimulation device intended for incomplete spinal cord injury rehabilitation in home-based care. Therefore, companies must align regulatory strategy, clinical study designs, and implementation workflows to the precise intersection of device type, therapeutic indication, care setting, enabling technology, and patient age group to maximize adoption and therapeutic relevance.

Regional considerations influencing clinical adoption, reimbursement approaches, and manufacturing strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics shape clinical adoption, reimbursement policy, and supply chain strategy, and three macro regions present distinct opportunities and constraints. In the Americas, decentralized healthcare delivery, advanced payer systems, and strong venture capital activity support commercialization of technologically sophisticated devices, but heterogeneity in reimbursement across federal and private payers requires tailored health economic evidence and localized market access plans. Europe, Middle East & Africa features diverse regulatory regimes, variable infrastructure, and a mix of public and private providers that necessitate flexible distribution models and partnership strategies; in parts of the region, centralized reimbursement authorities can accelerate uptake where evidence meets policy thresholds, whereas other areas demand localized pilots to demonstrate feasibility. The Asia-Pacific region exhibits rapid adoption in urban centers, strong manufacturing capabilities, and evolving reimbursement pathways; it also presents high demand for scalable, cost-effective solutions that can be adapted to large patient volumes and diverse care infrastructures.

Across these regions, stakeholders must consider differences in clinical practice patterns, caregiver availability, and digital health readiness. Consequently, go-to-market strategies that integrate region-specific clinical validation, reimbursement dossiers, and training programs will be better positioned to achieve sustainable adoption. Furthermore, strategic regional partnerships, investments in local regulatory expertise, and targeted value communication are essential to bridge clinical evidence with procurement decision-making across these varied geographies.

Competitive dynamics and capability imperatives shaping leadership positions, partnership models, and value-added service differentiation across the neurorehabilitation device ecosystem

Competitive dynamics in the neurorehabilitation device ecosystem are defined by a blend of established medtech firms, specialized boutique developers, academic spinouts, and cross-industry entrants. Leading companies emphasize multi-disciplinary R&D capabilities, robust regulatory pathways, and broad clinical evidence programs, while smaller innovators often focus on niche indications, disruptive technologies, and strategic collaborations to accelerate clinical validation. Across the competitive landscape, alliance formation-whether with academic centers, large health systems, or component suppliers-has become a core mechanism to accelerate product iteration and strengthen clinical credibility.

In addition, differentiated service models are emerging as a competitive lever. Firms that combine devices with software platforms for remote monitoring, analytics, and clinician support can offer higher perceived value to purchasers who prioritize longitudinal outcome measurement. Intellectual property around algorithms, sensor fusion, and therapeutic dosing also influences competitive positioning, as does the ability to demonstrate reproducible functional gains in heterogeneous patient populations. As a result, companies are increasingly investing in outcomes research, payer engagement, and scalable manufacturing to fortify commercial defensibility.

Practical strategic imperatives for leaders to align clinical evidence, modular product development, supply chain resilience, and payer engagement for sustainable growth

Industry leaders should adopt a dual-focus strategy that balances near-term commercialization with long-term platform development. First, prioritize clinical evidence generation targeted to high-impact indications and care settings where reimbursement pathways are mature, thereby creating reference cases that facilitate payer engagement and clinician advocacy. Concurrently, invest in modular product architectures and software-enabled services that can be iteratively updated, allowing companies to expand therapeutic indications and care pathways without full hardware redesigns.

Second, strengthen supply chain resilience through strategic supplier diversification, regional manufacturing investments, and flexible procurement contracts to reduce exposure to tariff-driven cost fluctuations and component shortages. Third, cultivate partnerships with health systems, rehabilitation networks, and academic centers to co-develop training curricula, remote monitoring workflows, and value dossiers that align clinical outcomes with procurement requirements. Finally, integrate robust post-market evidence capture and health economic modeling into commercial operations to translate clinical performance into payer-relevant value propositions, thereby accelerating coverage decisions and institutional procurement.

Transparent, multi-method research approach combining primary clinical interviews, technical literature synthesis, regulatory review, and supplier landscape analysis for robust insights

The research approach combines multi-source evidence gathering with expert consultation to build a rigorous, reproducible foundation for analysis. Primary research included structured interviews with clinicians, procurement leaders, and technology developers to capture real-world implementation challenges, clinical priorities, and adoption drivers. Secondary research drew on peer-reviewed clinical literature, regulatory guidance documents, and publicly available technical specifications to validate device capabilities and clinical use cases. In addition, supplier landscape mapping and patent analysis provided insight into technological differentiation and intellectual property trends.

Data synthesis involved triangulating qualitative insights with quantitative operational indicators such as clinical trial activity, regulatory approvals, and published health outcomes where available. Throughout the process, methodological rigor was maintained by applying standardized criteria for evidence weighting, transparency in assumptions, and iterative validation with domain experts. This approach ensures that conclusions reflect clinical realities, regulatory constraints, and commercial imperatives relevant to stakeholders across the development, deployment, and procurement lifecycle.

Synthesis of technological convergence, policy shifts, and operational imperatives informing strategic priorities for translating neurorehabilitation innovation into clinical impact

In conclusion, the neurorehabilitation device ecosystem is evolving from a collection of discrete technologies into integrated therapeutic platforms that prioritize continuity of care, demonstrable outcomes, and scalable delivery. Technological convergence across robotics, neuromodulation, brain-computer interfaces, and immersive environments is expanding therapeutic options while also raising the bar for clinical validation and interoperability. Meanwhile, policy shifts, tariff dynamics, and regional healthcare variances are reshaping supply chains, pricing strategies, and commercialization timelines.

As stakeholders navigate this complexity, success will hinge on aligning product design with specific clinical pathways, investing in evidence that resonates with payers and providers, and building resilient operational models that can adapt to geopolitical and regulatory changes. Those who combine rigorous clinical science with pragmatic commercialization strategies and cooperative partnerships will be best positioned to translate innovation into sustained patient benefit and organizational growth.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of closed-loop neuromodulation systems for personalized stroke rehabilitation therapy
  • 5.2. Integration of brain-computer interfaces with wearable exoskeletons to enhance motor recovery outcomes
  • 5.3. Utilization of virtual reality and gamification to drive patient engagement in neurorehabilitation programs
  • 5.4. Advancements in ultrasound neuromodulation techniques for noninvasive treatment of neurological disorders
  • 5.5. Growth of home-based robotic rehabilitation devices offering remote monitoring and teletherapy capabilities
  • 5.6. Emergence of AI-driven predictive analytics for optimizing personalized neurorehabilitation treatment pathways
  • 5.7. Development of implantable neural probes enabling real-time monitoring and adaptive stimulation protocols

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neurorehabilitation Devices Market, by Device Type

  • 8.1. Biofeedback System
    • 8.1.1. EMG Biofeedback
    • 8.1.2. Pressure Biofeedback
  • 8.2. Exoskeleton
    • 8.2.1. Lower Limb
    • 8.2.2. Upper Limb
  • 8.3. Functional Electrical Stimulation Device
    • 8.3.1. Implantable
    • 8.3.2. Surface
  • 8.4. Neuromodulation Device
    • 8.4.1. Invasive
    • 8.4.2. Noninvasive
  • 8.5. Virtual Reality System
    • 8.5.1. Immersive
    • 8.5.2. Nonimmersive

9. Neurorehabilitation Devices Market, by Application

  • 9.1. Cerebral Palsy
    • 9.1.1. Ataxic
    • 9.1.2. Dyskinetic
    • 9.1.3. Spastic
  • 9.2. Multiple Sclerosis
    • 9.2.1. Progressive
    • 9.2.2. Relapsing Remitting
  • 9.3. Parkinson's Disease
    • 9.3.1. Advanced Stage
    • 9.3.2. Early Stage
  • 9.4. Spinal Cord Injury
    • 9.4.1. Complete
    • 9.4.2. Incomplete
  • 9.5. Stroke
    • 9.5.1. Hemorrhagic
    • 9.5.2. Ischemic

10. Neurorehabilitation Devices Market, by End User

  • 10.1. Clinics
    • 10.1.1. General
    • 10.1.2. Specialty
  • 10.2. Home Care
    • 10.2.1. Assisted Living
    • 10.2.2. Self Managed
  • 10.3. Hospitals
    • 10.3.1. Private
    • 10.3.2. Public
  • 10.4. Rehabilitation Centers
    • 10.4.1. Inpatient
    • 10.4.2. Outpatient
  • 10.5. Research Institutes
    • 10.5.1. Academic
    • 10.5.2. Private

11. Neurorehabilitation Devices Market, by Technology

  • 11.1. Brain Computer Interface
    • 11.1.1. Invasive
    • 11.1.2. Noninvasive
  • 11.2. Robotics
    • 11.2.1. End Effector
    • 11.2.2. Exoskeleton
  • 11.3. Transcranial Direct Current Stimulation
    • 11.3.1. Anodal
    • 11.3.2. Cathodal
  • 11.4. Transcranial Magnetic Stimulation
    • 11.4.1. dTMS
    • 11.4.2. rTMS
  • 11.5. Virtual Reality
    • 11.5.1. Immersive
    • 11.5.2. Nonimmersive

12. Neurorehabilitation Devices Market, by Age Group

  • 12.1. Adult
    • 12.1.1. 18 To 40
    • 12.1.2. 41 To 64
    • 12.1.3. 65 Plus
  • 12.2. Geriatric
    • 12.2.1. 65 To 74
    • 12.2.2. 75 To 84
    • 12.2.3. 85 Plus
  • 12.3. Pediatric
    • 12.3.1. Adolescent
    • 12.3.2. Childhood
    • 12.3.3. Neonatal

13. Neurorehabilitation Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Neurorehabilitation Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Neurorehabilitation Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Medtronic plc
    • 16.3.2. Bioness, Inc.
    • 16.3.3. Hocoma AG
    • 16.3.4. Tyromotion GmbH
    • 16.3.5. Ekso Bionics Operations, Inc.
    • 16.3.6. ReWalk Robotics Ltd.
    • 16.3.7. Myomo, Inc.
    • 16.3.8. Bionik Laboratories Corp.
    • 16.3.9. Cyberdyne Inc.
    • 16.3.10. Hasomed GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NEUROREHABILITATION DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NEUROREHABILITATION DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. NEUROREHABILITATION DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEUROREHABILITATION DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BIOFEEDBACK SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BIOFEEDBACK SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BIOFEEDBACK SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BIOFEEDBACK SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BIOFEEDBACK SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BIOFEEDBACK SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BIOFEEDBACK SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BIOFEEDBACK SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EMG BIOFEEDBACK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EMG BIOFEEDBACK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EMG BIOFEEDBACK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EMG BIOFEEDBACK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EMG BIOFEEDBACK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EMG BIOFEEDBACK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRESSURE BIOFEEDBACK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRESSURE BIOFEEDBACK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRESSURE BIOFEEDBACK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRESSURE BIOFEEDBACK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRESSURE BIOFEEDBACK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRESSURE BIOFEEDBACK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY LOWER LIMB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY LOWER LIMB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY LOWER LIMB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY LOWER LIMB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY LOWER LIMB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY LOWER LIMB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY UPPER LIMB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY UPPER LIMB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY UPPER LIMB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY UPPER LIMB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY UPPER LIMB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY UPPER LIMB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY FUNCTIONAL ELECTRICAL STIMULATION DEVICE, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY FUNCTIONAL ELECTRICAL STIMULATION DEVICE, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY FUNCTIONAL ELECTRICAL STIMULATION DEVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY FUNCTIONAL ELECTRICAL STIMULATION DEVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY FUNCTIONAL ELECTRICAL STIMULATION DEVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY FUNCTIONAL ELECTRICAL STIMULATION DEVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY FUNCTIONAL ELECTRICAL STIMULATION DEVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY FUNCTIONAL ELECTRICAL STIMULATION DEVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMPLANTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMPLANTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMPLANTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMPLANTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMPLANTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMPLANTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SURFACE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SURFACE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SURFACE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SURFACE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SURFACE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SURFACE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NEUROMODULATION DEVICE, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NEUROMODULATION DEVICE, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NEUROMODULATION DEVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NEUROMODULATION DEVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NEUROMODULATION DEVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NEUROMODULATION DEVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NEUROMODULATION DEVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NEUROMODULATION DEVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INVASIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INVASIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INVASIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INVASIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INVASIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INVASIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONINVASIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONINVASIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONINVASIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONINVASIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONINVASIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONINVASIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMMERSIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMMERSIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMMERSIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMMERSIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMMERSIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMMERSIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONIMMERSIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONIMMERSIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONIMMERSIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONIMMERSIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONIMMERSIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONIMMERSIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CEREBRAL PALSY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CEREBRAL PALSY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CEREBRAL PALSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CEREBRAL PALSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CEREBRAL PALSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CEREBRAL PALSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CEREBRAL PALSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CEREBRAL PALSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ATAXIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ATAXIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ATAXIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ATAXIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ATAXIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ATAXIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DYSKINETIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DYSKINETIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DYSKINETIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DYSKINETIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DYSKINETIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DYSKINETIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPASTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPASTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPASTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPASTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPASTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPASTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PROGRESSIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PROGRESSIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PROGRESSIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PROGRESSIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PROGRESSIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PROGRESSIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RELAPSING REMITTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RELAPSING REMITTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RELAPSING REMITTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RELAPSING REMITTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RELAPSING REMITTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RELAPSING REMITTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EARLY STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EARLY STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EARLY STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPINAL CORD INJURY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPINAL CORD INJURY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY COMPLETE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY COMPLETE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY COMPLETE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY COMPLETE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY COMPLETE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY COMPLETE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INCOMPLETE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INCOMPLETE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INCOMPLETE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INCOMPLETE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INCOMPLETE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INCOMPLETE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY STROKE, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY STROKE, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HEMORRHAGIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HEMORRHAGIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HEMORRHAGIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HEMORRHAGIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HEMORRHAGIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HEMORRHAGIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ISCHEMIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ISCHEMIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ISCHEMIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ISCHEMIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ISCHEMIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ISCHEMIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY GENERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY GENERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY GENERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY GENERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY GENERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY GENERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPECIALTY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPECIALTY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPECIALTY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPECIALTY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPECIALTY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPECIALTY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ASSISTED LIVING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ASSISTED LIVING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ASSISTED LIVING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ASSISTED LIVING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ASSISTED LIVING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ASSISTED LIVING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SELF MANAGED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SELF MANAGED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SELF MANAGED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SELF MANAGED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SELF MANAGED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SELF MANAGED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRIVATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRIVATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRIVATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRIVATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PUBLIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PUBLIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PUBLIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PUBLIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REHABILITATION CENTERS, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REHABILITATION CENTERS, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY OUTPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RESEARCH INS